Bluejay Diagnostics, Inc. BJDX PHARMA
Company Overview
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -81.34% |
| 6 Months: | -44.92% |
| 3 Months: | -80.31% |
| 1 Month: | -3.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.55 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BJDX Bluejay Diagnostics, Inc. PHARMA | 1.03 | -0.45 | $1.07M | 0.00% | -115.88% | -98.89% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 249.04K | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | 48.91K | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -148.17K | -233.20K | -666.07K | -957.99K | -2.07M | -1.99M | -2.81M | -2.68M | -2.90M | -2.34M | -2.43M | -1.90M | -1.36M | -1.89M | -1.99M | -1.62M | -1.94M |
| Net Income | -127.99K | -194.19K | 640.23K | -1.19M | -2.01M | -1.94M | -2.96M | -2.54M | -2.81M | -2.30M | -2.33M | -2.48M | -1.48M | -1.86M | -1.96M | -1.60M | -1.92M |
| Diluted EPS | - | - | -0.15 | -0.11 | -0.10 | -2.00 | -2.94 | -2.49 | -22.00 | -16.67 | -394.76 | -256.16 | -76.94 | -13.46 | -1.41 | -1.01 | -1.95 |
| R&D Expense | 2.72K | 24.18K | 225.99K | 442.53K | 694.76K | 756.28K | 1.38M | 1.35M | 1.68M | 1.40M | 1.33M | 1.03M | 551.65K | 784.80K | 889.90K | 785.61K | 811.84K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 249.04K | - | - | - |
| Gross Profit | - | - | 48.91K | - | - | - |
| Operating Income | -1.20M | -3.23M | -9.32M | -10.31M | -7.17M | -6.95M |
| Net Income | -1.16M | -3.49M | -9.30M | -9.95M | -7.72M | -6.85M |
| Diluted EPS | - | -0.41 | -9.22 | -3,631.48 | -456.75 | -15.25 |
| R&D Expense | 527.25K | 1.15M | 4.15M | 5.71M | 3.47M | 3.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.52M | 21.02M | 13.52M | 4.87M | 6.66M | 7.12M |
| Total Equity | -2.93M | -4.21M | 20.38M | 11.54M | 2.89M | 5.73M | 5.98M |
| Cash & Equivalents | - | 912.36K | 19.05M | 10.11M | 2.21M | 4.30M | 5.16M |
| Total Liabilities | - | 1.85M | 637.16K | 1.98M | 1.97M | 927.92K | 1.14M |
| Current Liabilities | - | - | 637.16K | 1.64M | 1.77M | 810.37K | 1.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -508.71K | -4.37M | -7.74M | -8.31M | -7.82M | -6.05M |
| Investing Cash Flow | - | -23.95K | -1.20M | -704.17K | -306.78K | -173.74K |
| Financing Cash Flow | 1.33M | 22.53M | 8.07K | 1.11M | 10.22M | 7.09M |
| Capital Expenditure | - | -23.95K | -1.20M | -704.17K | -306.78K | -173.74K |
| Free Cash Flow | - | -4.39M | -8.94M | -9.02M | -8.13M | -6.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 19.6% | - | - | - |
| Operating Margin % | - | - | -3,741.5% | - | - | - |
| Net Margin % | - | - | -3,733.1% | - | - | - |
| ROE % | 27.5% | -17.1% | -80.6% | -343.8% | -134.7% | -114.6% |
| ROCE % | - | -15.8% | -78.4% | -332.9% | -122.6% | -115.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 2.93% | 131.00K | $120.52K |
| 2 | Heights Capital Management, Inc | 0.79% | 35.40K | $32.57K |
| 3 | Boothbay Fund Management, LLC | 0.61% | 27.13K | $24.96K |
| 4 | Vanguard Fiduciary Trust Co | 0.23% | 10.22K | $9.41K |
| 5 | Bank of America Corporation | 0.23% | 10.34K | $9.51K |
| 6 | Tower Research Capital LLC (TRC) | 0.04% | 1.91K | $1.75K |
| 7 | Caitong International Asset Management Co., Ltd | - | 1 | $0 |
| 8 | L1 Global Manager Pty Ltd | - | 120 | $110 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BJDX
$BJDX stock is up 16% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQR0l2TkdGT1hJN0pTZlAxSTM2QjNMQmNUWUQzUnJiSFRHLWQ1VmFqeW9XbkZsX0lXU19UaU1QZ0FKVlRZN3pfLUcwWXdPZzdoQXJ5OW9Cdk9FcHlKeXR3N2VxdFRFcC1rNWdqRE9TZ1dYQXNTR0Q5T0FKVVJwc2VJSm0wdlhLZHdWSlc4eV…
BJDX Stock Draws Traders As Cash, Trial And 13G Align - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQcFo5R3p6TWVHS2c2VG9KV2ltYnZReVdnMUJDQ0hHendwTHlTMG1QUm91eERlTUtsMmFxcWFwNmVxUl9JcEtOeXBsWFVvS3hZb3ZfeVlJaWtHdkRSRks0aERkVWdndXdIbTUxMzNWTld1eHNFYXd3MDVfeUJvaS1ielZB?oc=5" target=…
A medical test company is preparing for about 170 VA medical centers. FDA clearance or authorization comes first. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNYmgxTFVuR2pveFlJV3p4bTVwdFhrZmNiOXRjQmVKS2hDM3psLTZqU1BERFhjZE55RFFLUTZiRFY3aHI3eXROamJWTFZoaVJQVWxBc19PU2c5bVdYLWxRdlgyZGdUdlphZ09lakV5VWU4NTAxS2RKY1FPQVVoa1U4Qk44VEtCVDM5OWxBaE…
These stocks are moving in today's pre-market session - ChartMill
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPb3p2d3JWSExyd0NwT2RESGZqclBHdHhCaE9PYlN0aTd1RlRhVWNVN0FQdElTMmFFTC04QVp3WmtXdXdWUGk5blJfcURvN1dla3hYcXBCN3NidExFem91N1hqaUxYMTZhS2ZraHQ0eDdFMDNDTmNPSnVHancyWGxQYVB2UnVIWmY5azgyOD…
BJDX Stock Draws Traders As Trial, Cash Runway And 13G Align - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOQy1Hc1FzV3l4amQ0YnFrNS1tcE5kSmd1NDNZZ1c5RjluWXBXcUVCT01vSzJZTEFCVkJnRWMyalVhc25mb3FIbG5FMThUM2lCQXdRMXF1SmN5cFpfSmtNb3lvTWpoR2RiV0F3SHFOWWVSMllmV1ZrbzdFVzFnZWRWYzFVYzk?oc=5" targ…
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNSmdFOWg5OWUzNGpFTVFLRlJkU2lOaVp5OGNtREk2R3ZiQkgzZkZUX3RXRkx3S0pwOVMteXNGbk5Yd3ZHdWxtd2J3REtoamZOY1NlT0hWWDRrQWRNdHZ4STVnaUI1SGw2WHZCUUVTQ2o0eXpVLXpCUWpVVnRtQ1RXYzV4Xzg5UFVEeVVhLT…
BJDX — Frequently Asked Questions
What is the current share price of Bluejay Diagnostics, Inc. (BJDX)?
As of 2026-09-19 21:16 PDT, Bluejay Diagnostics, Inc. (BJDX) trades at $1.03 on NasdaqCM. Its 52-week range is $0.83 to $14.00.
What is the market capitalisation of BJDX?
Bluejay Diagnostics, Inc. (BJDX) has a market capitalisation of $1.07M on NasdaqCM.
What is the P/E ratio of BJDX?
BJDX trades at a trailing price-to-earnings (P/E) ratio of -0.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.21.
What is the return on equity (ROE) of BJDX?
BJDX has a return on equity (ROE) of -98.89%. Its return on capital employed (ROCE) is -115.88%.
Is BJDX a good stock to buy?
This page provides a data-driven analysis of Bluejay Diagnostics, Inc. (BJDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.